Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Panacea Biotec Ltd. Capital/Financing Update 2024

Dec 28, 2024

62573_rns_2024-12-28_6a8e0194-55b4-4c49-a99d-765b09d9afba.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [115 x 59] intentionally omitted <==

December 28, 2024

The Manager, Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Symbol: PANACEABIO

BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 BSE Scrip Code: 531349

Sub: Intimation of further investment in Panacea Biotec Inc. made by the Company’s material subsidiary, Panacea Biotec Pharma Limited

Ref.: Our letter dated June 22, 2024 under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

This is in continuation to our intimation letter dated June 22, 2024, wherein we have informed about the incorporation of wholly owned subsidiary company, Panacea Biotec Inc. (“PB Inc.”) by the Company’s material subsidiary, Panacea Biotec Pharma Limited (“PBPL”) and an investment of US$ 75,000 (~Rs.6.23 million) made by PBPL in the shares of common stock of PB Inc.

In this regard, we would like to further inform you that on December 27, 2024, PBPL made further investment of US$ 9,25,000 (~Rs.7.92 Crore) in PB Inc. as subscription for 9,25,00,000 shares of common stock of PB Inc. at a price of US$ 0.01 per share.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13[th] July, 2023, are given in Annexure A to this letter.

This is for your kind information and record please. Thanking you, Sincerely yours,

For Panacea Biotec Ltd.

Digitally signed by Vinod Goel Vinod Goel Date: 2024.12.28 12:25:08 +05'30'

Vinod Goel Group CFO and Head Legal & Company Secretary

Panacea Biotec Ltd (CIN: L33117PB1984PLC022350) Registered Office : Ambala-Chandigarh Highway, Lalru – 140501, Punjab Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India Ph.: 91-11-4167 9000, 4167 8000, Email: [email protected]

Annexure – A

==> picture [115 x 59] intentionally omitted <==

S.
No.
Particulars Details
i) Name of the target entity, details in
brief such as size, turnover etc.;
Panacea Biotec Inc.(“WOS”) was incorporated
as a wholly owned subsidiary company of the
Company’s material subsidiary viz. Panacea
Biotec Pharma Ltd. (“PBPL”).
Authorised Share Capital – 1 billion shares of
US$ 0.01 each aggregating to US$ 10 million.
Turnover: N.A.(Yet to commence business).
ii) Whether the acquisition would fall
within related party transaction(s) and
whether the promoter/ promoter
group/ group companies have any
interest in the entity being acquired?
If yes, nature of interest and details
thereof and whether the same is done
at arm’s length
Panacea Biotec Inc. being a step-down subsidiary
of the Company is a Related Party of the
Company and other group companies.
The investment made by PBPL in PB Inc. is in
the nature of related party transactions and is on
an arm’s length basis.
Save and except as above, none of the promoter /
promoter group / group companies of the
Companyhave anyinterest in WOS.
iii) Industry to which the entity being
acquired belongs
Healthcare
iv) Objects and impact of acquisition
(including
but
not
limited
to,
disclosure of reasons for acquisition
of target entity, if its business is
outside the main line of business of
the listed entity)
The WOS has been set-up with an objective of
establishing presence in the world’s largest
healthcare
market
in
US
by
pursuing
comprehensive range of activities, including the
buying, selling, marketing, importing, exporting,
distributing, and dealing in services and products
related to health and wellness, such as nutrition,
dietary supplements, OTC drugs, medical
devices, prescription drugs, and vaccines.
The investment made by PBPL in WOS is to
facilitate the capex and working capital
requirements of PB Inc. and is in furtherance of
its business. The business of the WOS is in line
with the business activities of the Company and
PBPL
v) Brief details of any governmental or
regulatory approvals required for the
acquisition
No such approval is required
vi) Indicative time period for completion
of the acquisition
Not Applicable
vii) Consideration
-
whether
cash
consideration or share swap or any
other form and details of the same
Cash

Panacea Biotec Ltd (CIN: L33117PB1984PLC022350) Registered Office : Ambala-Chandigarh Highway, Lalru – 140501, Punjab Vinod Digitally signed by Vinod Goel Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India Ph.: 91-11-4167 9000, 4167 8000, Email: [email protected] Goel Date: 2024.12.28 12:25:33 +05'30'

==> picture [115 x 59] intentionally omitted <==

S.
No.
Particulars Details
viii) Cost of acquisition and/or the price at
which the shares are acquired
PBPL has invested an amount of US$ 9,25,000
(~Rs.7.92 Crore) for acquisition of 9,25,00,000
shares of common stock of Panacea Biotec Inc. at
aprice of US$ 0.01per share.
ix) Percentage of shareholding / control
acquired and / or number of shares
acquired
PBPL will hold 100,000,000 shares of common
stock of WOS representing 100% of the issued
shareholdingtherein.
x) Brief background about the entity
acquired in terms of products/line of
business
acquired,
date
of
incorporation, history of last 3 years
turnover, country in which the
acquired entity has presence and any
other significant information (in
brief)
The main objects of the WOS shall encompass a
comprehensive range of activities, including the
buying, selling, marketing, importing, exporting,
distributing, and dealing in services and products
related to health and wellness, such as nutrition,
dietary supplements, OTC drugs, medical
devices, prescription drugs, and vaccines.
Date of incorporation: April 09, 2024
Turnover for the last 3 years: Not Applicable.
Country: United States of America

Vinod Digitally signed by Vinod Goel Goel Date: 2024.12.28 12:25:49 +05'30'

Panacea Biotec Ltd (CIN: L33117PB1984PLC022350) Registered Office : Ambala-Chandigarh Highway, Lalru – 140501, Punjab Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India Ph.: 91-11-4167 9000, 4167 8000, Email: [email protected]